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http://dx.doi.org/10Fanconi anemia (FA) is an inherited disorder of genomic instability associated with high risk
of myelodysplasia and acute myeloid leukemia (AML). Young mice deficient in FA core com-
plex genes do not naturally develop cancer, hampering preclinical studies on malignant hema-
topoiesis in FA. Here we describe that aging Fancc/ mice are prone to genomically unstable
AML and other hematologic neoplasms. We report that aneuploidy precedes malignant trans-
formation during Fancc/ hematopoiesis. Our observations reveal that Fancc/ mice
develop hematopoietic chromosomal instability followed by leukemia in an age-dependent
manner, recapitulating the clinical phenotype of human FA and providing a proof of concept
for future development of preclinical models of FA-associated leukemogenesis. Copyright 
2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).The Fanconi anemia (FA) signaling network protects
genomic integrity and prevents cancer by facilitating inter-
phase DNA repair and orchestrating cell division [1–3].
Germline biallelic mutations of any FA genes cause Fan-
coni anemia, an inherited bone marrow failure syndrome
associated with myelodysplasia (MDS) and acute myeloid
leukemia (AML). The overall risk of leukemia in FA is
increased six hundredfold [4].
Young mice deficient in core FA genes do not spontane-
ously recapitulate clinical hematopoietic manifestations of
Fanconi anemia [5]. Fancc/ mice demonstrate hypersen-
sitivity to cross-linking agents [6], decreased hematopoietic
stem cell repopulating ability [7,8], and hypersensitivity to
interferon-g [8], reflecting disruption of the FA signaling
network during hematopoiesis. However, young Fancc/
mice do not develop spontaneous leukemia or bone marrow
failure [6,8]. One observation study of a small Fancc/
mouse cohort (n 5 8) did not detect decreased survival
[9]. However, FA patients rarely develop AML in their first
year of life [10], and two soft tissue tumors (adenocarci-
noma and histiocytic sarcoma) have been reported in
O13-month-old Fancc/ mice [11]. Thus, we hypothe-
sized that aging Fancc/ mice may be predisposed toto: Grzegorz Nalepa, Wells Center for Pediatric
niversity School of Medicine, 1044 West Walnut
apolis, IN 46202; E-mail: gnalepa@iu.edu
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.1016/j.exphem.2016.01.009hematopoietic malignancies. If the absolute time to the
onset of leukemia is similar in FA humans and mice,
long-term observation of FA/ mice may be crucial to
detection of cancer predisposition. To address this transla-
tionally relevant question, we asked whether Fancc/
mice develop malignancies as they age.Methods
Mice
C57Bl/6J Fancc/ mice were a gift of David W. Clapp (Indiana
University). Mice were genotyped by polymerase chain reaction
(PCR), as described [9]. B6.SJL-PtprcaPepcb/BoyJ mice were pur-
chased from the Indiana University In Vivo Therapeutics Core. All
studies were approved by the Institutional Animal Care and Use
Committee at Indiana University.
Marrow harvest and transplantation
Bone marrow cells were flushed from mouse femurs using a 23-
gauge needle/syringe (Becton Dickinson). Light-density mononu-
clear cells (LDMNCs) were isolated by density gradient using
Histopaque-1119 (Sigma) and centrifuging for 30 min at
1,800 rpm with no brake. After centrifugation, LDMNCs were
removed from the interface and used for experiments. Cytospins
were made by resuspending LDMNCs in phosphate-buffered sa-
line (PBS) and centrifuging onto slides at 450 rpm for 5 min on
a Shandon Cytospin 3 Cytocentrifuge (Thermo Scientific). Donor
test LDMNCs (1.5  106, C57Bl/6J background) and donoratology. Published by Elsevier Inc. This is an open access article under the
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cipients via tail vein injection. Recipients were 8-week-old female
B6.SJL-PtprcaPepcb/BoyJ mice that underwent whole-body split-
dose 1,100-rad irradiation (700 rads/400 rads, 4 hours apart).
For chimerism analysis, peripheral blood was collected from
lateral tail veins into EDTA-coated tubes, incubated with red
blood cell lysis solution (Qiagen) for 10 min at room temperature,
washed, stained with anti-Cd45.2-flluorescein isothiocyanate (BD
Biosciences) and anti-Cd45.1-phycoerythrin (BD Biosciences), as
described [9], and analyzed on a FacsCalibur machine (Becton-
Dickinson). At least 10,000 events/sample were acquired and
analyzed using FlowJo Software.
Metaphase spreads
Bone marrow cells flushed from tibias were cultured in Iscove’s
modified Dulbecco’s medium (IMDM) plus 20% fetal bovine
serum, murine stem cell factor (100 ng/mL), and interleukin-6
(200 ng/mL) for 2 days. Cells were then exposed to 0.2 mg/mL
colcemid (Life Tech) for 4 hours and pelleted at 800 rpm for
5 min. Cells were resuspended dropwise in prewarmed (37C)
75 mM KCl and incubated at 37C for 15 min. After pelleting,
cells were resuspended in a 3:1 methanol:glacial acetic acid fixa-
tive. Cells were pelleted and resuspended in fixative two addi-
tional times before being dropped onto slides and dried
overnight. Spreads were stained with Vectashield mounting me-
dium with 40,6-diamidino-2-phenylindole (DAPI, Vector
Laboratories).
Histology and flow cytometry
Murine tissues obtained postmortem were fixed in 10% formalin,
paraffin-embedded, sectioned (5-mm sections), and stained with
hematoxylin and eosin. Peripheral blood smears and bone marrow
cytospins were stained with Giemsa, using the automated Siemens
Hematek 3000 (Fisher) system. For flow cytometry, peripheral
blood cells were incubated in RBC lysis solution, and bone
marrow LDMNCS were isolated as described above. Cells were
stained with either Gr-1-APC (Ly6G, clone: RB6-8C5) or B220-
FITC (clone: RA3-6B2) and analyzed on a FacsCalibur machine,
using live gating followed by data quantification with FlowJo soft-
ware. Leukemia diagnoses were made using criteria established in
the Bethesda proposal for classification of nonlymphoid neo-
plasms in mice [12], and were independently validated by a veter-
inary pathologist at the Indiana University School of Medicine.
Microscopy
Images of smears, cytospins, and histologic sections were obtained
using a Zeiss Axiolab microscope with a color camera. Metaphase
spreads were imaged on a Deltavision personalDx deconvolution
microscope (Applied Precision). Image stacks (distance between
z-sections: 0.2 mm) were deconvolved using Softworx and
analyzed using Imaris software suite (Bitplane).
Statistics
Statistical analysis was performed with GraphPad Prism 6 soft-
ware (GraphPad Software, La Jolla, CA).Results
We observed cohorts of wild-type (WT; n 5 20) and
Fancc/ (n 5 18) mice for 24 months and noticeddecreased survival of Fancc/ mice (p 5 0.01)
(Fig. 1A). Five Fancc/ mice (27.8%) died between 8
and 24 months of age from leukemia or lymphoma
(Fig. 1B–L). Specifically, we diagnosed AML in two mori-
bund Fancc/ mice with peripheral blasts, predominance of
Gr-1þ (Ly-6G) peripheral blood LDMNCs, and myeloid in-
filtrates around the liver vessels (Fig. 1C–E). One Fancc/
mouse developed lethal B-cell acute lymphoblastic leuke-
mia (ALL), as evidenced by expansion of B220þ blasts
that replaced O90% of bone marrow and infiltrated the
liver (Fig. 1F–H). Additionally, two Fancc/ mice died
from metastatic abdominal T-cell lymphoma manifested
by massive mesenteric lymph node conglomerates
(Fig. 1I–J) and accompanied by Cd3þ liver infiltrates
(Fig. 1K–L) in the absence of bone marrow or peripheral
blood abnormalities. After 24 months of observation, all
surviving Fancc/ and WT mice were sacrificed and
examined by necropsy. Four of 13 (30.8%) 2-year-old
Fancc/ animals had hematopoietic solid tumors and/or
peripheral blasts, consistent with leukemia/lymphoma. Se-
rial blood counts did not reveal progressive pancytopenia
in aging Fancc/ mice, suggesting that the development
of leukemia may not be preceded by bone marrow failure
in this animal model of FA. Nine of 18 Fancc/ mice
developed hematopoietic malignancies by 2 years of age
(including 5 animals that died prematurely from disease),
compared with zero of 20 control WT mice (p 5 0.0003)
(Fig. 1B). Thus, aging Fancc/ mice are prone to hemato-
poietic neoplasms, reflecting the age-dependent risk of leu-
kemia in FA patients [4,10,13].
We next asked whether Fancc/ AML can be propa-
gated in WT mice via competitive stem cell transplantation.
We mixed donor Fancc/ Cd45.2þ LDMNCs isolated
from a moribund AML Fancc/ mouse (Fig. 1C–E) with
WT Cd45.1þ competitor LDMNCs at a 1:1 ratio and trans-
planted the mixed cells into three lethally irradiated WT re-
cipients. Three WT recipients of age-matched WT Cd45.2þ
LDMNCs mixed with WT Cd45.1þ LDMNCs served as
controls (Fig. 2A). By 50 days posttransplantation, all re-
cipients of Fancc/ LDMNCs had died of AML, whereas
control recipients of WT LDMNCs remained healthy
(Fig. 2B). The diagnosis of AML was confirmed in all re-
cipients by flow cytometry, peripheral blood smears
(Fig. 2C), and splenomegaly (p 5 0.0216) (Fig. 2D). Pe-
ripheral blood flow cytometry revealed increased Cd45.2þ
chimerism (p 5 0.0436) in recipients of leukemic
Fancc/ LDMNCs compared with controls at 1 month
posttransplant (Fig. 2E, F), highlighting the malignant po-
tential of leukemic Fancc/ LDMNCs to outcompete
WT hematopoietic cells in the host marrow.
The FA signaling network maintains genomic integrity
during Fancc/ hematopoiesis in vivo [14], and genomic
instability promotes cancer [15]. Thus, we asked whether
leukemic Fancc/ mice exhibit increased chromosomal
instability and whether chromosomal instability precedes
Figure 1. Aging Fancc/ mice develop hematologic malignancies. (A) Kaplan–Meier survival curve of WT (n 5 20) and Fancc/ (n 5 18) cohorts. (B)
Table outlining incidence of leukemias and lymphomas in WT and Fancc/ mice by 24 months of age. Statistical significance for (A) and (B) was deter-
mined using a log-rank (Mantel–Cox) test. (C) Peripheral blood smear of a moribund Fancc/ mouse reveals leukemic blasts (arrows). (D, E) Diagnosis of
acute myeloid leukemia was confirmed with flow cytometry, which revealed (D) increased expression of the Gr1 myeloid marker in the peripheral blood
compared with WT and healthy Fancc/ controls (E) and the presence of leukemic infiltrates in the liver. (F) Bone marrow cytospin of another moribund
Fancc/ mouse revealed multiple blasts (arrows). (G, H) Flow cytometry indicated increased expression of the B220 B-cell marker on bone marrow blasts,
(G) and necropsy revealed leukemic infiltrates in the liver (H) consistent with B-cell ALL. (I, J) Necropsy of another Fancc/ mouse revealed conglom-
erates of mesenteric lymph nodes. (K, L) Liver infiltrates in this mouse were Cd3þ, consistent with T-cell lymphoma.
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Figure 2. Transplanted Fancc/ AML LDMNCs induce aggressive leukemia in WT recipients. (A) Schematic of competitive repopulation transplantation.
Cd45.2þ LDMNCs obtained from a leukemic Fancc/ mouse or WT control were mixed 1:1 with Cd45.1þ WT competitor LDMNCs and transplanted into
lethally irradiated WT recipients (n 5 3 recipients per genotype). (B) Recipients of Fancc/ LDMNCs died within 2 months of transplantation. A log-rank
(Mantel–Cox) test was used to assess significance. (C) AML in WT recipients of Fancc/ LDMNCs. Gr1 was used as a myeloid marker for flow cytometry
(right panel). (D) Splenomegaly in moribund WT mice transplanted with Fancc/ LDMNCs. (E, F) Leukemic Cd45.2þ Fancc/ LDMNCs overpopulate
recipient bone marrow compared with WT Cd45.1þ competitor LDMNCs. Statistical significance was determined using an unpaired Student t test; error bars
represent SEM.
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compared karyotypes of LDMNCs isolated from leukemic
Fancc/ with those of age-matched WT and healthy
Fancc/ marrows. Bone marrow cells isolated from
healthy Fancc/ mice had a higher incidence of aneu-
ploidy and an increased frequency of abnormal mitotic fig-
ures compared with WT LDMNCs (Fig. 3A–D), indicating
that Fancc/ hematopoietic cells become chromosomally
unstable before overt leukemogenesis occurs. Similarly,
FA patients develop hematopoietic chromosomal and nu-
clear abnormalities prior to the onset of leukemia
[14,16,17]. Leukemic Fancc/ bone marrows were
more aneuploid (Fig. 3B) with higher mitotic index
compared with both age-matched WT (p 5 0.001) and
Fancc/ nonleukemic (p ! 0.0001) (Fig. 3D) marrows.
This observation is consistent with further exacerbation
of genomic instability and acquisition of bizarre karyo-typic abnormalities reported in human FA-associated
AML [18,19].Discussion
Fancc/ mice develop chromosomally unstable hemato-
poietic malignancies as they age, recapitulating clinical
and genomic abnormalities seen in patients with Fanconi
anemia (Figs. 1 and 3). Interestingly, a similar incidence
of tumors has been reported in old mice deficient in
another FA core gene, Fanca, although that observation
has not reached statistical significance because of small
sample sizes [20]. Thus, late-onset carcinogenesis may
be a common phenotype of murine FA core gene knock-
outs. AML arising in Fancc/ mice can be propagated
via hematopoietic stem cell transplant and can produce
rapid onset of lethal leukemia in WT transplant recipients
Figure 3. Genomic instability and abnormal mitosis in leukemic and preleukemic Fancc/ mice. (A) Representative images of LDMNC metaphase spreads
from WT and leukemic Fancc/ mice. (B) Increased aneuploidy in leukemic Fancc/ LDMNCs. At least 74 spreads were counted from WT, Fancc/
nonleukemic, and Fancc/ leukemic mice. Note increased chromosomal instability in nonleukemic Fancc/ LDMNCs compared with age-matched
WT controls. Fisher’s exact test was used to determine statistical significance. (C, D) Leukemic Fancc/ LDMNCs undergo abnormal mitosis (C) and
have a higher mitotic index (D) compared with LDMNCs from WT and Fancc/ nonleukemic mice (n 5 3 mice/genotype; at least 500 cells were
counted per genotype). Statistical analyses were performed using c2 tests with Yates correction.
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essential for preclinical drug testing, our observations
may facilitate the development of future preclinical
models of FA/ AML.Acknowledgments
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